JBI-802
Phase 2- Indications
- Essential Thrombocythemia, Myeloproliferative Neoplasms, Non-small cell lung cancer
Company intelligence / Profile preview
Jubilant Pharmova has a broad commercial portfolio including radiopharmaceuticals (diagnostic/therapeutic), allergy immunotherapy products with leading US market share in several categories. Its proprietary drug pipeline focuses on precision oral medicines for oncology and autoimmunity at the clinical stage. The company also provides global CDMO/CRDMO services including APIs and sterile injectables
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jubilant Pharmova Limited.